Radiation Oncology for Uveal Melanoma and Prostate Cancer
This community focuses on the clinical application of radiation therapy, specifically brachytherapy and external beam radiotherapy, for the treatment of uveal melanoma and localized prostate cancer.
The research is dominated by the management of uveal melanoma, with a strong emphasis on plaque brachytherapy using isotopes such as iodine-125 and ruthenium-106. A significant portion of the work addresses localized prostate cancer, focusing on high-dose-rate brachytherapy, seed implantation, and external beam radiation. The literature also includes studies on dose calculation methods, such as Monte Carlo simulations, and clinical outcomes related to quality of life and treatment complications. While uveal melanoma is the primary subject, the community also encompasses work on squamous cell carcinoma and other ocular surface conditions treated with radiation.
The largest share of the community's output is found in radium research, accounting for 4.4% of all radium research, and 817 papers here. Iodine research follows with 681 papers, representing 0.4% of iodine research, and iridium research contributes 389 papers, or 0.9% of iridium research.
The community comprises 7,799 papers, published primarily in the International Journal of Radiation OncologyBiologyPhysics, The British Journal of Radiology, and the British Journal of Ophthalmology.
Recent work continues to focus on metastatic uveal melanoma, including clinical trials for targeted therapies like tebentafusp and hepatic perfusion, as well as the development of novel staging models and the integration of machine learning for predicting local recurrence after brachytherapy.